FI821253L - GALENISK PRODUCT - Google Patents

GALENISK PRODUCT

Info

Publication number
FI821253L
FI821253L FI821253A FI821253A FI821253L FI 821253 L FI821253 L FI 821253L FI 821253 A FI821253 A FI 821253A FI 821253 A FI821253 A FI 821253A FI 821253 L FI821253 L FI 821253L
Authority
FI
Finland
Prior art keywords
active compound
calcium
galenisk
product
antagonistic
Prior art date
Application number
FI821253A
Other languages
Finnish (fi)
Other versions
FI821253A0 (en
Inventor
Heinz Einig
Volker Buehler
Winfried Koch
Joachim Arthur Schwarz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6129505&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI821253(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Publication of FI821253A0 publication Critical patent/FI821253A0/en
Publication of FI821253L publication Critical patent/FI821253L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1. A pharmaceutical composition which contains a calcium-antagonistic active compound, with or without additional active compounds, is intended for oral administration to produce a sustained action for continuous therapy and contains only the sustaining dose of active compound, bound to pharmaceutical auxiliaries, wherein the calcium-antagonistic active compound is Gallopamil or Verapamil and wherein, at the sustaining dose, the ratio of the constituents with rapid release of active compound to those with sustained release of active compound is from 1 : 0.6 to 1 : 6.
FI821253A 1981-04-07 1982-04-07 GALENISK PRODUCT FI821253L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813113901 DE3113901A1 (en) 1981-04-07 1981-04-07 ACTIVE SUBSTANCE PREPARATION FOR ORAL APPLICATION

Publications (2)

Publication Number Publication Date
FI821253A0 FI821253A0 (en) 1982-04-07
FI821253L true FI821253L (en) 1982-10-08

Family

ID=6129505

Family Applications (1)

Application Number Title Priority Date Filing Date
FI821253A FI821253L (en) 1981-04-07 1982-04-07 GALENISK PRODUCT

Country Status (17)

Country Link
EP (1) EP0063266B1 (en)
JP (1) JPS57175113A (en)
AT (1) ATE14076T1 (en)
AU (1) AU555093B2 (en)
CA (1) CA1184497A (en)
DE (2) DE3113901A1 (en)
DK (1) DK157482A (en)
ES (1) ES511208A0 (en)
FI (1) FI821253L (en)
GR (1) GR74770B (en)
HU (1) HU186855B (en)
IE (1) IE52985B1 (en)
IL (1) IL65328A (en)
NO (1) NO157204C (en)
NZ (1) NZ200244A (en)
PT (1) PT74705B (en)
ZA (1) ZA822327B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
LU86077A1 (en) * 1985-09-18 1987-04-02 Pharlyse Sa NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
LU86099A1 (en) * 1985-09-30 1987-04-02 Pharlyse EXTENDED RELEASE GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (en) * 1988-03-23 1989-10-05 Knoll Ag MIXTURE OF ALGINATES AND POLYACRYLATES AND THEIR USE
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
EP0366868B1 (en) * 1988-07-13 1992-09-30 Knoll Ag Substained release pharmaceutical composition containing alginate
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE3932378A1 (en) * 1989-09-28 1991-04-11 Knoll Ag SOLID MEDICAL FORM WITH A HIGH VERAPAMIL CONTENT
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (en) * 1961-04-01 1963-09-26 Knoll Ag Process for the preparation of basic substituted phenylacetonitriles
DE1467781A1 (en) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients

Also Published As

Publication number Publication date
PT74705B (en) 1983-11-14
DE3264519D1 (en) 1985-08-08
AU8238482A (en) 1982-10-14
IE52985B1 (en) 1988-04-27
EP0063266A2 (en) 1982-10-27
IL65328A (en) 1985-06-30
EP0063266A3 (en) 1983-05-04
NZ200244A (en) 1984-08-24
AU555093B2 (en) 1986-09-11
CA1184497A (en) 1985-03-26
ZA822327B (en) 1983-03-30
DK157482A (en) 1982-10-08
NO821084L (en) 1982-10-08
GR74770B (en) 1984-07-12
ES8307496A1 (en) 1983-08-16
JPS57175113A (en) 1982-10-28
ES511208A0 (en) 1983-08-16
EP0063266B1 (en) 1985-07-03
NO157204C (en) 1988-02-10
NO157204B (en) 1987-11-02
HU186855B (en) 1985-10-28
PT74705A (en) 1982-05-01
IL65328A0 (en) 1982-05-31
ATE14076T1 (en) 1985-07-15
FI821253A0 (en) 1982-04-07
DE3113901A1 (en) 1982-10-28
IE820812L (en) 1982-10-07

Similar Documents

Publication Publication Date Title
FI821253L (en) GALENISK PRODUCT
ATE154354T1 (en) AZABICYCLIC COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THERAPEUTIC USE
NO171365C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZIMIDAZOLD DERIVATIVES
DE69127470T2 (en) REINFORCING REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS
FR2422620A1 (en) STILBENE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
ATE194987T1 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
DE60022895D1 (en) PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
ATE38151T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE 5-ADENOSYL-L-METHIONINE SALTS FOR ORAL USE.
OA09209A (en) "Thienotriazolo-diazepine derivatives, a process for the preparation of said compounds and a therapeutic composition containing them".
MX9203361A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING GALIUM CHLORIDE.
IT1241079B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCEDURE FOR THEIR PREPARATION AND RELATED THERAPEUTIC USE
ATE18203T1 (en) (-)-15-DEOXYSPERGUALIN, ITS MANUFACTURE AND MEDICATIONS CONTAINING THIS ACTIVE SUBSTANCE.
FI923662A (en) THERAPEUTIC MEDEL
ATE85218T1 (en) ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF HYPERTENSION WITH DILTIAZEM HYDROCHLORIDE ONCE DAILY.
KR910018026A (en) Drugs for treating urination disorders containing α-phenyl-αpyridylalkanoic acid derivatives
KR890007737A (en) Anti-caking agents
MX9302929A (en) DERIVATIVES OF TETRAHIDRO AND PERHIDROISOQUINOLINA AND THERAPEUTICAL MEDIA THAT CONTAIN THEM.
IL87867A (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
TH3319EX (en) Methods for preparation N- (2-Pyrityl) -2-methyl-4-hydroxy-2H-1,2-benzothiazin-3-carboxamide -1,1 an Oxide
ATE15041T1 (en) ANTI-PAIN RELIEF, ANTI-INFLAMMATORY AND ANTIPYREXIC COMPOUND, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: BASF AKTIENGESELLSCHAFT